Darbepoetin can be administered either intravenously (i.v.) or subcutaneously (s.c.). However, no information is available regarding pharmacokinetics and pharmacodynamics following its i.v.
Previous studies suggest that darbepoetin might stimulate erythropoiesis in preterm neonates more effectively if injected subcutaneously (s.c.) than if infused intravenously (i.v.). It has been ...
Patient characteristics are summarized in Table 1 . A total of 14 patients received at least one dose of darbepoetin alfa, and the 12 who received more than one dose were assessable. Eleven patients ...
THOUSAND OAKS, Calif., (March 27, 2006) – Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved every-three-week ...
THOUSAND OAKS, Calif., September 7, 2006 -- Amgen (NASDAQ: AMGN) today announced the launch of the Aranesp® (darbepoetin alfa) prefilled SureClick TM autoinjector for patients with ...
BARCELONA, Spain -- Sept. 26, 2007--Amgen today announced data from a Phase 2, randomized, multicenter, open-label study that suggest extended dosing of Aranesp(R) (darbepoetin alfa) paired with ...
The US Food and Drug Administration (FDA) has approved epoetin and darbepoetin for chemotherapy-induced anemia (CIA). Approved epoetin and darbepoetin dosing schedules were three times per week and ...
NEW YORK, April 19 (Reuters) - Amgen Inc.'s. anemia drug Aranesp showed no increased risk of death compared to a placebo in a study of small-cell lung cancer patients undergoing chemotherapy, sending ...
LOS ANGELES (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died compared ...
The potential risk of stroke has been listed on Aranesp's label since the drug was approved in 2001, but "we will definitely update the label" because of the new study's results, he said. Aranesp did ...
This was a 15-week, open-label, nonrandomized, prospective, pilot study. The protocol and informed-consent form were approved by the clinical investigational review board at SHHS. Patients were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results